(Redirected from Analgesics)An 'analgesic' (colloquially known as a 'painkiller') is any member of the diverse group of
drugs used to relieve
pain (achieve ''analgesia''). This derives from Greek ''an-'', "without", and ''-algia'', "pain". Analgesic drugs act in various ways on the
peripheral and
central nervous systems; they include
paracetamol (acetaminophen), the
nonsteroidal anti-inflammatory drugs (NSAIDs) such as the
salicylates,
narcotic drugs such as
morphine, synthetic drugs with narcotic properties such as
tramadol, and various others. Some other classes of drugs not normally considered analgesics are used to treat
neuropathic pain syndromes; these include
tricyclic antidepressants and
anticonvulsants.
The major classes
Paracetamol and NSAIDs
The exact mechanism of action of paracetamol/acetaminophen is uncertain, but it appears to be acting centrally.
Aspirin and the other
NSAIDs inhibit
cyclooxygenase, leading to a decrease in
prostaglandin production; this reduces pain and also
inflammation (in contrast to paracetamol and the opioids).
Paracetamol has few side effects, but dosing is limited by possible
hepatotoxicity (potential for
liver damage). NSAIDs may predispose to
peptic ulcers,
renal failure,
allergic reactions, and
hearing loss. They may also increase the risk of
hemorrhage by affecting
platelet function. The use of certain NSAIDs in children under 16 suffering from viral illness may contribute to
Reye's syndrome.
COX-2 inhibitors
Main articles: COX-2 inhibitor
These drugs have been derived from NSAIDs. The
cyclooxygenase enzyme inhibited by NSAIDs was discovered to have at least 2 different versions: COX1 and COX2. Research suggested that most of the adverse effects of NSAIDs were mediated by blocking the COX1 (constitutive) enzyme, with the analgesic effects being mediated by the COX2 (inducible) enzyme. The COX2 inhibitors were thus developed to inhibit only the COX2 enzyme (traditional NSAIDs block both versions in general). These drugs (such as
rofecoxib and
celecoxib) are equally effective analgesics when compared with NSAIDs, but cause less gastrointestinal hemorrhage in particular. However post-launch data indicated increased risk of cardiac and cerebrovascular events with these drugs, and rofecoxib was subsequently withdrawn from the market. The role for this class of drug is
currently hotly debated.
Opiates and morphinomimetics
Morphine, the archetypal opioid, and various other substances (e.g.
codeine,
oxycodone,
hydrocodone,
diamorphine,
pethidine) all exert a similar influence on the cerebral
opioid receptor system.
Tramadol and
buprenorphine are thought to be
partial agonists of the opioid receptors. Dosing of all opioids may be limited by opioid toxicity (confusion, respiratory depression,
myoclonic jerks and pinpoint pupils), but there is no dose ceiling in patients who tolerate this.
Opioids, while very effective analgesics, may have some unpleasant side-effects. Up to 1 in 3 patients starting morphine may experience
nausea and
vomiting (generally relieved by a short course of
antiemetics).
Pruritus (itching) may require switching to a different opioid.
Constipation occurs in almost all patients on opioids, and
laxatives (
lactulose,
macrogol-containing or
co-danthramer) are typically co-prescribed.
When used appropriately, opioids and similar
narcotic analgesics are safe and effective, carrying relatively little risk of
addiction. Occasionally, gradual tapering of the dose is required to avoid withdrawal symptoms.
Specific agents
In patients with chronic or neuropathic pain, various other substances may have analgesic properties.
Tricyclic antidepressants, especially
amitriptyline, have been shown to improve pain in what appears to be a central manner. The exact mechanism of
carbamazepine,
gabapentin and
pregabalin is similarly unclear, but these
anticonvulsants are used to treat neuropathic pain with modest success.
Specific forms and uses
Combinations
Analgesics are frequently used in combination, such as the paracetamol and
codeine preparations found in many non-prescription pain relievers. They can also be found in combination with vasoconstrictor drugs such as
pseudoephedrine for
sinus-related preparations, or with
antihistamine drugs for allergy sufferers.
The use of paracetamol, as well as aspirin, ibuprofen, naproxen, and other
NSAIDS concurrently with weak to mid-range opiates (up to about the hydrocodone level) has been shown to have beneficial synergistic effects by combating pain at multiple sites of action—NSAIDs reduce inflammation which, in some cases, is the cause of the pain itself while opiates dull the perception of pain—thus, in cases of mild to moderate pain caused in part by inflammation, it is generally recommended that the two are prescribed together.
[1]
Topical or systemic
Topical analgesia is generally recommended to avoid systemic side-effects. Painful joints, for example, may be treated with an
ibuprofen- or
diclofenac-containing gel;
capsaicin also is used topically.
Lidocaine and
steroids may be injected into painful joints for longer-term pain relief.
Lidocaine is also used for painful
mouth sores and to numb areas for
dental work and minor medical procedures.
Psychotropic agents
Tetrahydrocannabinol (THC) and some other
cannabinoids, either from the ''
Cannabis sativa'' plant or synthetic, have analgesic properties, although the use of cannabis derivatives is illegal in many countries. Other psychotropic analgesic agents include
ketamine (an NMDA receptor antagonist),
clonidine and other α
2-adrenoreceptor agonists, and
mexiletine and other local anaesthetic analogues.
Atypical and/or adjuvant analgesics
Orphenadrine,
cyclobenzaprine,
scopolamine,
atropine,
gabapentin, first-generation
antidepressants and other drugs possessing
anticholinergic and/or
antispasmodic properties are used in many cases along with analgesics to potentiate centrally acting analgesics such as
opioids when used against pain especially of neuropathic origin and to modulate the effects of many other types of analgesics by action in the
parasympathetic nervous system.
Dextromethorphan has been noted to slow the development of tolerance to opioids and exert additional analgesia by acting upon the
NMDA receptors; some analgesics such as
methadone and
ketobemidone and perhaps
piritramide have intrinsic NMDA action.
The use of
adjuvant analgesics is an important and growing part of the pain-control field and new discoveries are made practically every year. Many of these drugs combat the side effects of opioid analgesics, an added bonus. For example,
antihistamines including orphenadrine combat the release of histamine caused by many opioids,
methylphenidate,
caffeine,
ephedrine,
dextroamphetamine, and
cocaine work against heavy sedation and may elevate mood in distressed patients as do the antidepressants. The one indisputably true benefit of THC to chronic pain patients on opioids may be its superior anti-nauseant action. However, it would make more sense to use the Marinol capsule, or oral, rectal, or vapour administration of hash oil, rather than smoking cannabis, for the same reasons most doctors advise against smoking tobacco.
Addiction
In the
United States in recent years, there has been a wave of new
addictions to prescription narcotics such as
oxycodone (Percocet) and
hydrocodone (
Vicodin, Lortab etc.) when available in pure formulations as opposed to combined with other medications (as in
Percocet which contains both oxycodone and acetaminophen/paracetamol). Hydrocodone is only available in pure form in some European countries as the original hydrocodone pharmaceutical, Dicodid tablets. Far from reducing addiction liability, the paracetamol content of many codeine, dihydrocodeine, hydrocodone, and oxycodone pharmaceuticals in the United States only saddles users with the high risk of severe liver damage, and extraction of the opioids with cold water or solvents reduces this problem for the sophisticated abuser, self-medicator, and legitimate prescription holder alike
[2].
See also
★
Pain management
★
Patient-controlled analgesia
★
Co-proxamol
References
★ ''Cancer pain relief and palliative care''. Report of a WHO expert committee [World Health Organization Technical Report Series, 804] . Geneva, Switzerland: World Health Organization; 1990. pp. 1–75. ISBN 92-4-120804-X.
★
Bandolier pain site (Oxford pain group)
External links
★
FDA proposes new pain reliever warnings